Oxford Biomedica Strengthens Board with Key Appointment

Oxford BioMedica (GB:OXB) has released an update.

Oxford Biomedica has appointed Colin Bond as a Non-Executive Director, effective January 2025, as part of its board succession planning. Bond brings extensive experience in the biopharma and CDMO sectors, having played key roles in companies like Sandoz and Vifor Pharma. This strategic move is aimed at bolstering Oxford Biomedica’s growth and innovation in the cell and gene therapy industry.

For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.